Why AI matters at this scale

enco pharmaceutical development, inc. (EPDI) is a contract development and manufacturing organization (CDMO) founded in 2005 and based in Jacksonville, Florida. With a workforce of 1,001–5,000 employees, EPDI provides comprehensive services to biotech and pharmaceutical companies, spanning drug formulation, analytical testing, clinical trial material manufacturing, and commercial-scale production. As a mid-market player, EPDI operates in a highly competitive and regulated sector where speed, efficiency, and reliability are critical to retaining clients and maintaining margins.

At this scale, AI adoption transitions from experimental to strategic. A company of EPDI's size has sufficient data volume and operational complexity to justify AI investments, yet it must compete with larger CDMOs that have deeper R&D budgets. AI offers a lever to differentiate services, compress development timelines, and optimize costly manufacturing processes. For a mid-market CDMO, the imperative is to do more with existing resources—AI can augment scientific expertise, reduce material waste, and unlock new revenue streams through data-driven insights, directly impacting the bottom line and client satisfaction.

Three concrete AI opportunities with ROI framing

1. AI-Powered Formulation Development: Drug formulation is a trial-and-error process that consumes significant time and expensive active pharmaceutical ingredients (APIs). Machine learning models trained on historical formulation data can predict stable and bioavailable combinations, potentially reducing the number of experimental batches by 30–50%. This directly accelerates time-to-clinical trials for clients, a key selling point, while lowering EPDI's material costs. ROI manifests in increased project throughput and higher-margin service offerings.

2. Predictive Maintenance in Manufacturing: Unplanned downtime in sterile filling or tablet compression lines can cost hundreds of thousands per hour and risk batch failures. Implementing AI-driven predictive maintenance using IoT sensor data can forecast equipment failures weeks in advance, scheduling maintenance during planned outages. This improves overall equipment effectiveness (OEE), reduces costly emergency repairs, and ensures on-time delivery for clients. The ROI includes higher asset utilization and reduced capital expenditure on spare machinery.

3. Intelligent Clinical Trial Support: EPDI often supports sponsors in clinical trial material logistics and protocol execution. AI tools can analyze diverse datasets—electronic health records, genomic data, past trial results—to optimize patient recruitment, identify ideal clinical sites, and even suggest adaptive trial designs. This reduces trial delays, a major pain point for sponsors, and positions EPDI as a strategic partner rather than a mere supplier. ROI is realized through premium service fees and increased win rates for complex projects.

Deployment risks specific to this size band

For a mid-market company like EPDI, AI deployment carries distinct risks. Financial constraints mean investments must show clear, relatively quick ROI; pilot projects need careful scoping. Talent acquisition is challenging—competing with tech giants and large pharma for data scientists requires creative hiring or partnerships. Data infrastructure may be fragmented across legacy systems (e.g., ERP, LIMS), requiring upfront investment in integration before AI models can be trained effectively. Regulatory uncertainty looms large; using AI in GMP environments requires rigorous validation and may face cautious FDA scrutiny. Finally, change management across 1,000+ employees necessitates strong leadership to overcome skepticism and upskill staff, ensuring AI tools are adopted and not shelved.